Phathom Pharmaceuticals, Inc.

NasdaqGS PHAT

Phathom Pharmaceuticals, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2024: USD -0.00

Phathom Pharmaceuticals, Inc. Dividend Per Share is USD -0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Dividend per share represents the dividends distributed per share. Indicates dividend yield potential on a per-share basis.
  • Phathom Pharmaceuticals, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -0.00, a 0.00% change year over year.
  • Phathom Pharmaceuticals, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -0.00, a 0.00% change year over year.
  • Phathom Pharmaceuticals, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -0.00, a 0.00% change year over year.
  • Phathom Pharmaceuticals, Inc. Dividend Per Share for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -0.00.
Key data
Date Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA) Return on Equity (ROE)
Market news
NasdaqGS: PHAT

Phathom Pharmaceuticals, Inc.

CEO Ms. Terrie J. Curran
IPO Date Oct. 25, 2019
Location United States
Headquarters 100 Campus Drive
Employees 452
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Similar companies

INZY

Inozyme Pharma, Inc.

USD 1.51

-12.21%

KNSA

Kiniksa Pharmaceuticals, Ltd.

USD 18.34

0.94%

TERN

Terns Pharmaceuticals, Inc.

USD 4.57

-4.79%

ABOS

Acumen Pharmaceuticals, Inc.

USD 1.56

-1.89%

CGEM

Cullinan Oncology, Inc.

USD 10.01

-9.33%

DAWN

Day One Biopharmaceuticals, Inc.

USD 11.16

-3.46%

IMMX

Immix Biopharma, Inc.

USD 2.00

-5.66%

GPCR

Structure Therapeutics Inc.

USD 25.38

0.87%

BPMC

Blueprint Medicines Corporation

USD 102.56

-0.77%

AMLX

Amylyx Pharmaceuticals, Inc.

USD 3.13

-1.57%

StockViz Staff

January 15, 2025

Any question? Send us an email